慢性免疫介导性皮肤病多组学分析:SKINERGY研究方案与策略性评估
研究通过多组学(含血液、皮肤活检、胶带剥离、拭子、影像等)在真实临床治疗下随访1年,旨在建立机器学习就绪数据集,识别用于疾病分层和治疗反应的生物标志物。
要点
- 研究采集多组学数据(血液、皮肤活检、胶带剥离、拭子、影像、远程医疗和患者报告结局),随访1年。
- 目标是通过机器学习识别生物标志物,指导靶向治疗选择和预测治疗反应。
核心结论
- SKINERGY研究将生成机器学习就绪数据集,识别可能指导靶向治疗选择、提升治疗反应和加深疾病病理理解的生物标志物谱。
研究设计与样本
- 多中心、平行队列、开放标签、观察性、纵向篮式研究,纳入AD 120例、PSO 160例、HS 80例、CSU 120例、CLE 120例,每组治疗亚组N≤40例。
- 匹配健康志愿者120例和MF队列120例作为对照;患者真实世界治疗开始后随访1年,核心评估在基线、第3个月和第6个月,可选12个月随访。
- 健康志愿者对照组120例未治疗,监测3个月;患者权益组织共同定义研究议程并参与研究设计和知情同意书开发。
主要发现
- 研究将生成包含组织学、代谢组学、空间蛋白质组学、转录组学、脂质组学、微生物组学、影像生物标志物、远程医疗、PROMs和临床参数随时间变化信息的数据集。
关键数值与推荐
- 纳入五种疾病患者总数:AD 120例、PSO 160例、HS 80例、CSU 120例、CLE 120例,每组治疗亚组N≤40例。
- 对照设置:匹配健康志愿者120例和MF队列120例;健康志愿者对照组120例未治疗,监测3个月。
- 核心评估时间点:基线(首剂前)、第3个月和第6个月;可选12个月随访、补充问卷和皮肤钻孔活检。
临床怎么用
- 研究在真实临床环境中进行,评估生物标志物用于疾病分层和靶向治疗反应,可能辅助临床治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)' will be conducted as a multicentre, parallel-cohort, open-label, observational, longitudinal basket study. OBJECTIVES: Objectives include evaluation of disease-related characteristics in comparison to those of healthy volunteers and evaluation of biomarkers for disease stratification and (targeted) treatment response in patients in a real-world clinical setting. Additionally, differences and similarities in disease characteristics between diseases, changes over time, and profiles of responders versus non-responders will be evaluated. METHODS: Patients with AD (N = 120), PSO (N = 160), HS (N = 80), CSU (N = 120) and CLE (N = 120) will be enrolled in groups of N ≤ 40 patients per treatment. Matched healthy volunteers (N = 120) and the MF cohort (N = 120) will serve as control groups. Assessments include blood sampling, skin punch biopsies, tape stripping, skin swabs, (multimodal) imaging, tele-health and patient- and physician-reported outcomes. This manuscript describes the study protocol prior to data collection and its strategic evaluation of multi-omics profiling. Patient advocacy groups co-defined the research agenda and contributed to study design and informed consent document development, ensuring alignment with patients' needs and real-world relevance. RESULTS: SKINERGY will generate a machine learning-ready dataset with information about changes in various biomarkers over time, including histology, metabolomics, spatial proteomics, transcriptomics, lipidomics, microbiomics, imaging biomarkers, tele-health, patient-reported outcome measures (PROMs) and clinical parameters. CONCLUSIONS: Identified biomarker profiles within SKINERGY may guide targeted treatment selection, enhance targeted therapeutic response in clinical practice and improve understanding of disease pathology in chronic immune-mediated skin diseases. The SKINERGY study will investigate disease mechanisms of five immune‐mediated inflammatory skin diseases, namely atopic dermatitis, psoriasis, hidradenitis suppurativa, chronic spontaneous urticaria and cutaneous lupus erythematosus. Chronic inflammatory skin conditions are estimated to affect up to 25% of the population. The study is designed to compare mechanisms of these inflammatory skin diseases with an external cohort of patients with cutaneous T‐cell lymphoma subtype mycosis fungoides and healthy volunteers. The SKINERGY study is a nationwide initiative, with patient inclusion occurring across all university medical centres in the Netherlands. The main aim of the SKINERGY study is to generate a harmonized dataset suitable for advanced computer analysis in order to identify biomarkers for disease monitoring and enabling prediction of (non)‐response to treatment. This is an observational study, in which 720 patients will be followed for 1 year after initiating real‐world treatment in routine clinical settings. Several parameters will be assessed at baseline (prior to the first dose), Month 3 and Month 6 (core study). Optional assessments include a 12‐month follow‐up visit, supplementary questionnaires and skin punch biopsies. Additionally, a control group of 120 untreated healthy volunteers will be monitored over a 3‐month period. Ultimately, the study seeks to discover biomarkers that can guide treatment selection, facilitating more precise and personalized treatment strategies for patients with inflammatory skin diseases.
引用
- Koster NG, van den Reek JMPA, de Jong EMGJ, et al. Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation. J Eur Acad Dermatol Venereol. 2026. PMID: 41645921. doi:10.1111/jdv.70311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。